Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-747.40% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
MGRX · Jun 30, 2025
MANGOCEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001493152-25-023566General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
3.03% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
53.51% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-3133.98% · CORE · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
30.32% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History15 statesHistory building
Mar 31, 20230/5 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/6 normalizedLevel 3Dec 31, 20230/6 normalizedLevel 3Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/6 normalizedLevel 3Sep 30, 20240/6 normalizedLevel 3Dec 31, 20240/5 normalizedLevel 3Mar 31, 20254/5 normalizedLevel 3Jun 30, 20254/5 normalizedLevel 3Jun 30, 20254/5 normalizedAmended as filedSep 30, 20254/5 normalizedLevel 3Dec 31, 20254/5 normalizedLevel 3Mar 31, 20265/5 normalizedLevel 3Jun 30, 20265/5 normalizedLevel 3
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.